A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
Primary Objective
To evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera in maintaining hematocrit control.
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Brandon Mcmahon, MD
Study ID
Protocol Number: 22-0305
More information available at ClinicalTrials.gov: NCT05210790
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers